AG
DAWN

Algert Global’s Day One Biopharmaceuticals DAWN Stock Holding History

Algert Global’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-535,290
Closed -$4.99M – 1202
2025
Q4 		$4.99M Sell
535,290
-781,752
-59% -$6.53M 0.08% 439
2025
Q3 		$9.29M Buy
1,317,042
+411,000
+45% +$2.83M 0.16% 207
2025
Q2 		$5.89M Buy
906,042
+534,662
+144% +$3.68M 0.12% 278
2025
Q1 		$2.94M Buy
+371,380
New +$4M 0.07% 471
2024
Q4 		– Sell
-71,487
Closed -$996K – 1202
2024
Q3 		$996K Buy
71,487
+50,990
+249% +$728K 0.03% 748
2024
Q2 		$282K Sell
20,497
-4,545
-18% -$66.5K 0.01% 1145
2024
Q1 		$414K Hold
25,042
– – 0.02% 812
2023
Q4 		$366K Sell
25,042
-8,020
-24% -$97.2K 0.01% 902
2023
Q3 		$406K Sell
33,062
-15,940
-33% -$208K 0.02% 810
2023
Q2 		$585K Buy
49,002
+31,622
+182% +$413K 0.03% 780
2023
Q1 		$232K Buy
+17,380
New +$340K 0.01% 997

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Algert Global's DAWN Position: Q1 2026 in Review

Algert Global sold out of Day One Biopharmaceuticals (DAWN) in Q1 2026, closing a stake of 535,290 shares — an estimated $4.99M sold.

Algert Global first reported a position in DAWN in Q1 2023 and held it in 11 quarters. The position peaked at $9.29M in Q3 2025. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Algert Global reported no remaining Day One Biopharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Algert Global sold 535,290 Day One Biopharmaceuticals shares in Q1 2026, an estimated $4.99M.
  • Algert Global first reported a position in Day One Biopharmaceuticals in Q1 2023 and held it in 11 quarters.
  • Algert Global's Day One Biopharmaceuticals position peaked at $9.29M in Q3 2025.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Algert Global's 13F filing for Q1 2026, filed 14 May 2026.